# PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/pik3ca-related-overgrowth-spectrum-pros-proteus-syndrome-ps

> 2 upcoming FDA catalysts in PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS): miransertib (MRK) on Feb to May 2030 (topline data readout); miransertib (MRK) on February 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb to May 2030 | [Miransertib topline data readout](https://sec-api.dev/pdufa/miransertib) | MRK | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | scheduled | "NCT04980872 (A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04980872)) |
| February 2030 | [Miransertib primary completion](https://sec-api.dev/pdufa/miransertib) | MRK | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | scheduled | "NCT04980872 (A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04980872)) |

## Drugs

- [Miransertib](https://sec-api.dev/pdufa/miransertib) (MRK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/pik3ca-related-overgrowth-spectrum-pros-proteus-syndrome-ps.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/pik3ca-related-overgrowth-spectrum-pros-proteus-syndrome-ps

```bibtex
@misc{secapidev_indications_pik3ca_related_overgrowth_spectrum_pros_proteus_syndrome_ps_20261116,
  title        = {PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/pik3ca-related-overgrowth-spectrum-pros-proteus-syndrome-ps}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_pik3ca_related_overgrowth_spectrum_pros_proteus_syndrome_ps_20261116","title":"PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/pik3ca-related-overgrowth-spectrum-pros-proteus-syndrome-ps","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
